# Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine

> **NCT00981630** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 128 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **BIOLOGICAL:** Live attenuated Japanese encephalitis virus
- **BIOLOGICAL:** Live attenuated Japanese encephalitis virus
- **BIOLOGICAL:** Live attenuated Japanese encephalitis virus
- **BIOLOGICAL:** ChimeriVax™ diluent (Placebo)

## Key facts

- **NCT ID:** NCT00981630
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-02
- **Final completion:** 2007-11
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2012-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981630, "Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00981630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*